| Symphogen–Selexis: cell line development, 201412– license to SUREtechnology platform + SURE CHO-M Cell Line + collab RnD |
2014-12-09 |
| BioCat GmbH–Genetrix (ES): TruePrime, 201412– distribution non-excl of Sygnis’ TruePrime Single Cell WGA kit by BioCat |
2014-12-08 |
| KWS Saat–Metabolomic Discoveries: metabolomic services, 201412– supply service 3y to study + improve KWS crops on biochemical level |
2014-12-05 |
| Sigma-Aldrich–MIT: CRISPR technology, 201412– non-excl license to foundational CRISPR patents from Broad Institute |
2014-12-04 |
| Anergis–SEVERAL: investment, 201412 financing round Series B CHF14.5m (€12.1m) co-led by Sunstone Capital + BioMedInvest + Renaissance PME + WJFS |
2014-12-03 |
| Ariosa Diagnostics–Roche: investment, 201412–2015 acquisition $625m by Roche |
2014-12-02 |
| Ayoxxa–SEVERAL: investment, 201412 financing round Series B extension €2.3m from BioMedPartners AG + Grazia Equity GmbH |
2014-12-02 |
| Bayer–Orion Corp: cancer drug, 201412 existent collab ww developm + marketing of oral androgen receptor modulator ODM-201 for prostate cancer |
2014-12-02 |
| BioVersys–Enamine: drug discovery services, 201412– collab extension €na supply services for discovery of new antibiotics |
2014-12-02 |
| Xeltis–Kurma: investment, 201412 financing round Series B totalling €27m co-led by LSP + Kurma Partners |
2014-12-02 |
| Xeltis–Life Sciences Partners: investment, 201412 financing round Series B totalling €27m co-led by LSP + Kurma Partners |
2014-12-02 |
| Xeltis–SEVERAL: investment, 201412 financing round Series B €27m co-led by LSP + Kurma Partners plus VI Partners + current investors |
2014-12-02 |
| Xeltis–VI Partners: investment, 201412 financing round Series B totalling €27m incl co-investor VI Partners |
2014-12-02 |
| InnoLife project–EU (govt): grant, 201412– KIC grant of up to €700m out of a total project volume >€2b |
2014-12-01 |
| Nanolive–SEVERAL: investment, 201412 closing of 1st financing round |
2014-12-01 |
| Pieris–MacDougall Biomedical Communications: public relations, 201412 service existent |
2014-12-01 |
| Sartorius–SEVERAL: credit, 201412– syndicated €400m 5-year loan from bank syndicate led by BNP Paribas + Commerzbank + LBBW |
2014-12-01 |
| Tiziana–Novimmune: therapeutic antibody, 201412– license to foralumab (NI-0401) to Tiziana |
2014-12-01 |
| Uniqure–MacDougall Biomedical Communications: public relations, 201412 service existent |
2014-12-01 |
| Boehringer–NanoPET Pharma: contrast medium, 201411– collab development of contrast media for use in preclinical research |
2014-11-30 |
| WeissBioTech–BRAIN: investment, 201411 acquisition €na of majority shareholding in WeissBioTech GmbH by BRAIN AG |
2014-11-27 |
| Promethera–SEVERAL: investment, 201411 financing round Series C €20.33m incl new investors SFPI-FPIM + SMS Investments |
2014-11-25 |
| Promethera–Wallonia (govt): credit, 201411 loans + subisidies totalling €5m to support clinical development of HepaStem + collab w EMD-Millipore |
2014-11-25 |
| PS Biotech–SEVERAL: investment, 201411 financing round Series A |
2014-11-25 |
| Curetis–Life Sciences Partners: investment, 201411 financing round Series B extension totalling €14.5m incl €7m from new investors LSP-HEF + Qiagen |
2014-11-24 |
| Curetis–Qiagen: investment, 201411 financing round Series B extension totalling €14.5m incl €7m from two new investors Qiagen + LSP-HEF |
2014-11-24 |
| Curetis–SEVERAL: investment, 201411 financing round Series B extension €14.5m new investors Qiagen + LSP-HEF + all existing investors |
2014-11-24 |
| AstraZeneca–Biognosys: mass spectrometry services, 201411– supply Proteome-SEQ service to AstraZeneca |
2014-11-21 |
| BioNano Genomics–Novartis: investment, 201411 financing round Series C totalling $53m co-led by new investor Novartis Venture Fund |
2014-11-20 |
| Bionano Genomics–SEVERAL: investment, 201411 financing round Series C $53m co-led by new investors Legend Capital + Novartis Venture Fund |
2014-11-20 |
| MagForce–SEVERAL: investment, 201411 capital increase €10.2m placing 1.7m new shares €6/share |
2014-11-20 |
| NEU² project–Metabolomic Discoveries: biomarker discovery, 201411– collab to identify metabolomic markers for MS with Fraunhofer IME + UKE |
2014-11-20 |
| Roche–Axxam: drug discovery services, 201411– supply drug screening + assay development services by Axxam + HDC |
2014-11-19 |
| Allylix–Evolva: investment, 201411–201412 acquisition merger for 46m new Evolva shares representing 14.1% post-merger share |
2014-11-18 |
| Evolva–Cargill: investment, 201411 investment $4m to support merger acquisition of Allylix by Evolva |
2014-11-18 |
| Intellia Therapeutics–Atlas Venture: investment, 201411 financing round Series A totalling $15m led by Atlas Venture + Novartis |
2014-11-18 |
| Intellia Therapeutics–Novartis: investment, 201411 financing round Series A totalling $15m led by Atlas Venture + Novartis |
2014-11-18 |
| Intellia Therapeutics–SEVERAL: investment, 201411 financing round Series A $15m led by Atlas Venture + Novartis |
2014-11-18 |
| Pepperprint–Sciomics: microarray technology, 201411– collab distribution + marketing for antibody characterisation + biomarker discovery |
2014-11-18 |
| Pfizer–Merck (DE): antibody cancer drug, 201411– collab dev + commerc of anti-PD-L1 antibody $850m upfront + $2b milestones + shared costs + revenues |
2014-11-17 |
| Protagen–BioStrata: public relations, 201411 service existent by BioStrata |
2014-11-17 |
| Qiagen–Protagen: proteomic companion diagnostics, 201410– collab €na developm for autoimmune therapies using SeroTag platform |
2014-11-17 |
| Cogent Healthcare–Fresenius: investment, 201411– acquisition €na of Cogent by Sound Physicians Inc ANNOUNCED |
2014-11-13 |
| Univ Furtwangen–Danaher: mass spectrometer, 201411 supply existent AB Sciex QTRAP 4000 system used by Prof Fath for water analysis |
2014-11-13 |
| Novartis–Qiagen: molecular companion diagnostics, 201411– collab €na master agreement devlepm + commercialisation of CDx for Novartis drugs |
2014-11-11 |
| Histide–SEVERAL: investment, 201411 financing round Series A CHF4.5m ($4.6m) led by Parter Capital + private investors |
2014-11-10 |
| Humedics–SEVERAL: investment, 201411 financing round Series C €6.3 led by new investors Vesalius Biocapital Partners + Seventure Partners |
2014-11-10 |
| Siemens–SEVERAL: investment, 201411 acquisition of Siemens Audiology Solutions for €2.15b plus earn-out by EQT + Strüngmann family |
2014-11-06 |
| Definiens–AstraZeneca: investment, 201411 acquisition $150m upfront + milestones by MedImmune |
2014-11-04 |
| Bruker–Techcomp: investment, 201411 acquisition of GC + GC-SQ SCION business by Techcomp Europe Ltd |
2014-11-03 |
| Dihon Pharmaceutical–Bayer: investment, 201411 acquisition for CNY3.6b=€460m |
2014-11-03 |
| Quanta Fluid Solutions–SEVERAL: investment, 201411 financing round £27m led by new investor ALIAD |
2014-11-03 |
| Covance–LabCorp: investment, 201411–201502 acquisition $6.2b w $107.19/share paid $75.76 in cash + 0.26886 LabCorp shares per Covance share |
2014-11-02 |
| EBOKON project–Germany (govt): grant, 201411–201512 BMBF grant €2.3m to DZIF + partners for Ebola virus research |
2014-11-01 |
| Servier–GeNeuro: GNbAC1 MAb, 201411– collab developm + marketing for MS w excl license option ww excl US+JP $47m upfront + $408 milestones + royalties |
2014-11-01 |
| MYR GmbH–High-Tech Gründerfonds: investment, 201410 financing round totalling €7.9m from Maxwell Biotech Venture Fund + HTGF |
2014-10-31 |
| MYR GmbH–Russia (govt): investment, 201410 financing round totalling €7.9m from Maxwell Biotech Venture Fund + HTGF |
2014-10-31 |
| MYR GmbH–SEVERAL: investment, 201410 financing round €7.9m from Maxwell Biotech Venture Fund + HTGF |
2014-10-31 |
| Deutsche Messe–Select Biosciences: European Lab Automation conference, 201410–201510 collab co-hosting of ELA 2015 + Labvolution 2015 in Hannover |
2014-10-30 |
| Bayer–DuPont: herbicides, 201410–201412 acquisition €na approx 30 herbicides for land management from DuPont Crop Protection by Bayer CropScience |
2014-10-29 |
| Eurofins–Igenbio: genomic services, 201410– collab product integration for one-stop-shopping solution by Eurofins Genomics + Igenbio |
2014-10-29 |
| Affimed–Distributed Bio: antibody technology, –201410 co-development of AbAccel technology platform with AbCheck |
2014-10-28 |
| Astellas–Qiagen: molecular companion diagnostics, 201410– collab €na master agreement devlepm + commercialisation of CDx for Astellas drugs |
2014-10-28 |
| Cunesoft–Bavaria (govt): investment, 201410 financing round with HTGF + Bayern Kapital |
2014-10-28 |
| Cunesoft–High-Tech Gründerfonds: investment, 201410 financing round with HTGF + Bayern Kapital |
2014-10-28 |
| Cunesoft–SEVERAL: investment, 201410 financing round with HTGF + Bayern Kapital |
2014-10-28 |
| Imevax–BioMedPartners: investment, 201410 financing round Series A totalling €7.5m incl co-lead investor BioMedInvest-II LP fund |
2014-10-28 |
| Imevax–EMBL: investment, 201410 financing round Series A totalling €7.5m incl co-lead investor EMBL Ventures |
2014-10-28 |
| Imevax–MC Services: public relations, 201410 service existent by MC Services AG |
2014-10-28 |
| Imevax–SEVERAL: investment, 201410 financing round Series A €7.5m led by Wellington Partners |
2014-10-28 |
| Imevax–Strüngmann Group: investment, 201410 financing round Series A totalling €7.5m incl co-lead investor Santo Venture Capital |
2014-10-28 |
| Imevax–Wellington Partners: investment, 201410 financing round Series A totalling €7.5m incl lead investor Wellington Partners |
2014-10-28 |
| National Cardiovascular Partners–Fresenius: investment, 201410 acquisition €na of NCP by Fresenius Medical Care |
2014-10-22 |
| YES Pharma Services–Auctus Capital: investment, 201410 acquisition of majority share by funds advised by Auctus Capital Partners AG |
2014-10-22 |
| VBC-Biotech–Eurofins: investment, 201410 acquisition merger establishing Eurofins Genomics AT GmbH taking over VBC services |
2014-10-21 |
| Weizmann Institute–XL-protein: PASylation technology, 201410– Yeda acquires ww excl marketing + outlicensing rights to PAS-YNSa8 dev by XL + Weizmann |
2014-10-21 |
| Univ Lausanne–Thermo Fisher: mass spectrometer, 201410 supply existent Bertrand Rochat early access user of Q Exactive Focus LC-MS/MS system |
2014-10-20 |
| Epigenomics–BioChain: investment, 201410 acquisition €4.2m 1.35m new shares €3.08/share by BioChain Institute Inc |
2014-10-16 |
| Roche–NewLink Genetics: cancer drugs, 201410– collab drug discovery IDO/TDO inhibitors with Genentech |
2014-10-16 |
| MorphoSys–Lanthio Pharma: LanthioPep technology, 201410 acquisition €na technology + all related IP by MorphoSys |
2014-10-15 |
| Bicylce Therapeutics–SEVERAL: investment, 201410 financing round £20m incl Atlas Venture + Novartis VF + SR One + SVLS + Astellas Venture |
2014-10-14 |
| Raze Therapeutics–SEVERAL: investment, 201410 financing round Series A $24m from Atlas Venture + MPM + MS Ventures + PIF + Astellas + Novartis |
2014-10-14 |
| Rigontec–Boehringer: investment, 201410 financing round Series A 1st closing totalling €9.45m co-led by Wellington Partners + BIVF |
2014-10-14 |
| Rigontec–High-Tech Gründerfonds: investment, 201410 financing round Series A 1st closing totalling €9.45m incl co-investor HTGF |
2014-10-14 |
| Rigontec–Huntsworth: public relations, 201410 service existent by Citigate Dewe Rogerson |
2014-10-14 |
| Rigontec–North Rhine-Westphalia (govt): investment, 201410 financing round Series A 1st closing totalling €9.45m incl co-investor NRW.Bank |
2014-10-14 |
| Rigontec–SEVERAL: investment, 201410 financing round Series A 1st closing €9.45m co-led by Wellington Partners + BIVF |
2014-10-14 |
| Rigontec–Wellington Partners: investment, 201410 financing round Series A 1st closing totalling €9.45m co-led by Wellington Partners + BIVF |
2014-10-14 |
| Probiodrug–Hume Brophy: public relations, 201410 service existent by Hume Brophy |
2014-10-10 |
| 4 Animals AlsterScience–Hamburg (govt): investment, 201410 seed financing round from HTGF + Innovationsstarter Fonds + Business Angel |
2014-10-09 |
| 4 Animals AlsterScience–High-Tech Gründerfonds: investment, 201410 seed financing round from HTGF + Innovationsstarter Fonds + Business Angel |
2014-10-09 |
| 4 Animals AlsterScience–SEVERAL: investment, 201410 seed financing round from HTGF + Innovationsstarter Fonds + Business Angel |
2014-10-09 |
| Roche–AbVitro: PETE technology, 201410 acquisition €na of primer extension based target enrichment technology by Roche |
2014-10-09 |
| Mimetas–SEVERAL: investment, 201510 financing round $5.2m from ZIF + PPM Oost et al |
2014-10-08 |
| Horizon Discovery–Haplogen: cell lines, 201410– distribution ww of cell line engineering services + Haplogen human knockout cell lines by Horizon |
2014-10-06 |
| TVM–SEVERAL: investment, 201410 final closing of $201.6m fund TVM Life Science Ventures VII incl Teralys Capital + Lilly |
2014-10-06 |
| Cell Marque–Sigma-Aldrich: investment, 201410–201411 acquisition €na of Cell Marque Corp by Sigma-Aldrich |
2014-10-03 |
| Forbion–SEVERAL: investment, 201410 first close €92m of FCF III fund with target size of €150–200m |
2014-10-03 |
| Danaher–Illumina: OneOmics cloud computing environment, 201410– collab product integration Illumina NGS w AB Sciex SWATH proteomics on BaseSpace |
2014-10-02 |
| Abionic–SEVERAL: investment, 201410 financing round Series B CHF3.8m |
2014-10-01 |
![[LSG] Life-Sciences-Germany.com - The Life Sciences Web Portal for German-speaking Europe](/images/basics/lsg-life-sciences-germany-portal-logo-2019.png){kind=logo}
![Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 650x65px](/banner/iito-20181119-650-065-lse-life-sciences-europe-com.jpg)
1 2 3 ... 29 30 31 ... 53 54 55 
Date![Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 650x65px](/banner/iito-20181119-650-065-lsus-life-sciences-usa-com.jpg)
![Picture [iito] LSE iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20111029-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px](/banner/iito-20150801-120-600-lse-life-sciences-europe-com.jpg)
